GlaxoSmithKline plc Share Price LIQUIDNET SYSTEMS

Equities

GSK

GB0009252882

Pharmaceuticals

Delayed LIQUIDNET SYSTEMS 5-day change 1st Jan Change
- EUR -.--% Intraday chart for GlaxoSmithKline plc -0.40% -.--%

Financials

Sales 2024 * 31.63B 40.19B 37.03B 3,163B Sales 2025 * 33.58B 42.68B 39.32B 3,358B Capitalization 72.39B 91.98B 84.74B 7,239B
Net income 2024 * 5.54B 7.05B 6.49B 554B Net income 2025 * 6.49B 8.25B 7.6B 649B EV / Sales 2024 * 2.68 x
Net Debt 2024 * 12.29B 15.61B 14.38B 1,229B Net Debt 2025 * 9.07B 11.52B 10.62B 907B EV / Sales 2025 * 2.43 x
P/E ratio 2024 *
12.9 x
P/E ratio 2025 *
11.1 x
Employees -
Yield 2024 *
3.43%
Yield 2025 *
3.56%
Free-Float 94.54%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on GlaxoSmithKline plc

Managers TitleAgeSince
Chief Executive Officer 55 30/04/10
Director of Finance/CFO 62 30/04/23
Compliance Officer - 31/07/95
Members of the board TitleAgeSince
Director of Finance/CFO 62 30/04/23
Chairman 66 31/08/19
Director/Board Member 62 31/12/17
More insiders
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.75 GBP
Average target price
20.32 GBP
Spread / Average Target
+14.50%
Consensus